CHICAGO (EGMN) —Maintenance therapy with bevacizumab fell short of statistical non-inferiority to maintenance with standard XELOX chemotherapy plus bevacizumab for metastatic colorectal cancer, but that may not matter when quality of life is considered, according to investigators from the MACRO trial of the Spanish Cooperative Group for the Treatment of Digestive Tumors."This study suggests that maintenance therapy with single-agent bevacizumab [Avastin] may be an appropriate treatment option following...